These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 26795288

  • 1. The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer.
    van Rossum PS, Fried DV, Zhang L, Hofstetter WL, van Vulpen M, Meijer GJ, Court LE, Lin SH.
    J Nucl Med; 2016 May; 57(5):691-700. PubMed ID: 26795288
    [Abstract] [Full Text] [Related]

  • 2. Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging 18F-FDG PET Imaging Biomarkers in Patients with Esophageal Cancer.
    Beukinga RJ, Hulshoff JB, Mul VEM, Noordzij W, Kats-Ugurlu G, Slart RHJA, Plukker JTM.
    Radiology; 2018 Jun; 287(3):983-992. PubMed ID: 29533721
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients.
    Kim SJ, Koo PJ, Chang S.
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):723-31. PubMed ID: 26891957
    [Abstract] [Full Text] [Related]

  • 4. 18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma.
    Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH.
    J Nucl Med; 2017 Nov; 58(11):1756-1763. PubMed ID: 28522744
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma.
    van Rossum PSN, Fried DV, Zhang L, Hofstetter WL, Ho L, Meijer GJ, Carter BW, Court LE, Lin SH.
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):71-80. PubMed ID: 27511188
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M, Alnaji RM, Jabi F, Platz TA, Attwood K, Nava H, Ben-David K, Mattson D, Salerno K, Malhotra U, Kanehira K, Gannon J, Hochwald SN.
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [Abstract] [Full Text] [Related]

  • 9. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
    Purandare NC, Pramesh CS, Karimundackal G, Jiwnani S, Agrawal A, Shah S, Kulkarni M, Laskar SG, Rangarajan V.
    Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
    [Abstract] [Full Text] [Related]

  • 10. Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation.
    Arnett ALH, Merrell KW, Macintosh EM, James SE, Nathan MA, Shen KR, Ravi K, Neben Wittich MA, Haddock MG, Hallemeier CL.
    J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
    Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW.
    J Clin Oncol; 2010 Nov 01; 28(31):4714-21. PubMed ID: 20876421
    [Abstract] [Full Text] [Related]

  • 14. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V, Lucey JA, Duffy GJ, Wilson L, McNamara L, Keogan M, Gillham C, Reynolds JV.
    J Nucl Med; 2010 Dec 01; 51(12):1863-9. PubMed ID: 21078796
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy.
    Tandberg DJ, Cui Y, Rushing CN, Hong JC, Ackerson BG, Marin D, Zhang X, Czito BG, Willett CW, Palta M.
    Int J Radiat Oncol Biol Phys; 2018 Nov 15; 102(4):1002-1007. PubMed ID: 30055238
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M, Neoral C, Vrba R, Vomackova K, Cincibuch J, Formanek R, Koranda P, Zapletalova J.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun 15; 156(2):171-9. PubMed ID: 22660205
    [Abstract] [Full Text] [Related]

  • 19. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
    Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A.
    J Gastrointest Cancer; 2012 Dec 15; 43(4):612-8. PubMed ID: 22777832
    [Abstract] [Full Text] [Related]

  • 20. The value of 18F-FDG-PET testing in the management of esophageal and gastroesophageal junction adenocarcinoma - review.
    Zemanová M, Obermannová R, Haruštiak T.
    Klin Onkol; 2021 Dec 15; 34(2):113-119. PubMed ID: 33906359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.